Aurora Cannabis will be trading on the NYUSE under the ticker symbol “ACB.” The company has the capability of producing over 500,000 kg’s of dried cannabis flower per year and currently owns operations in 18 countries, on 5 different continents. Aurora has developed all of their facilities to meet EU GMP standards in order to scale their company internationally.
Aurora Cannabis owns a plethora of wholly owned subsidiaries, totaling 15, which includes: MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland , H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC Lab.
Over the years their company has grown into one of the most respected public companies involved in the sector. Over the past year Aurora Cannabis’s stock has increased in price from $2.82 per share in October, 2017 to $13.94 per share today. The company also has a current market cap of $13.4 billion dollars, making it one of the largest cannabis companies in the world.
“Aurora has rapidly developed into a globally mature organization with industry leading and technologically advanced production facilities available to produce at unprecedented scale to meet the growing demand for high-quality cannabis both in Canada and abroad. We are also uniquely committed to leveraging our deep knowledge base to further scientific research into medical applications of cannabis, and developing novel, higher-margin product offerings that strongly differentiate Aurora from our competition,” said Terry Booth, Aurora Cannabis CEO, in the press release.